Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | -100.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.37% | +9.29% | -5.03% | +55.88% | +85.46% |
| Weighted Average Shares Diluted Growth | +9.37% | +9.29% | -5.03% | +55.88% | +85.46% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +169.53% | +57.42% |
| Asset Growth | +23.93% | +33.92% | +31.50% | +12.25% | +16.31% |
| Book Value per Share Growth | -29.42% | -30.07% | -20.05% | -38.16% | -34.08% |
| Debt Growth | -52.27% | +148.59% | +488.00% | +589.81% | +794.39% |
| R&D Expense Growth | -18.87% | +4.45% | -41.34% | -43.68% | -24.79% |
| SG&A Expenses Growth | -19.81% | -34.93% | -8.94% | -85.42% | +6.18% |